Suche >
Tetrabutylazanium+trifluoro(3-fluorophenyl)boranuide
Drucken
Sie suchten nach:
86 768 results were found
Tetrabutylazanium+trifluoro(3-fluorophenyl)boranuide
Artikel-Nr:
(APOSOR01559-1G)
Lieferant:
APOLLO SCIENTIFIC
Hersteller-Artikelnummer::
OR01559-1G
Lokale Artikelnummer::
APOSOR01559-1G
Beschreibung:
1-Methylimidazo[1,5-a]pyridine
VE:
1 * 1 g
Artikel-Nr:
(SIAL183946-5G)
Lieferant:
Sigma-Aldrich
Hersteller-Artikelnummer::
183946-5G
Lokale Artikelnummer::
SIAL183946-5G
Beschreibung:
6-(Chlormethyl)uracil, Sigma-Aldrich®
VE:
1 * 5 g
Artikel-Nr:
(MOLE14554862-1G)
Lieferant:
Molekula
Hersteller-Artikelnummer::
14554862-1G
Lokale Artikelnummer::
MOLE14554862-1G
Beschreibung:
2'-Desoxycytidin Hydrochlorid
VE:
1 * 1 g
 This is a MarketSource item. Additional charges may apply
Artikel-Nr:
(J65456.03)
Lieferant:
Alfa Aesar
Hersteller-Artikelnummer::
J65456.03
Lokale Artikelnummer::
ALFAJ65456.03
Beschreibung:
5-Bromo-2′-deoxycytidine 99%
VE:
1 * 1 g
Lieferant:
Alfa Aesar
Beschreibung:
15-Hydroxypentadecansäure ≥99%
Artikel-Nr:
(APOSOR936911-500G)
Lieferant:
APOLLO SCIENTIFIC
Hersteller-Artikelnummer::
OR936911-500G
Lokale Artikelnummer::
APOSOR936911-500G
Beschreibung:
3-Methyl-1,5-pentandiol 95%
VE:
1 * 500 g
Artikel-Nr:
(APOSOR52237-5G)
Lieferant:
APOLLO SCIENTIFIC
Hersteller-Artikelnummer::
OR52237-5G
Lokale Artikelnummer::
APOSOR52237-5G
Beschreibung:
1,5-Diphenylcarbazon 95%, technische Qualität
VE:
1 * 5 g
Lieferant:
APOLLO SCIENTIFIC
Beschreibung:
1,5-Naphthyridin-4-ol 95%
Artikel-Nr:
(BOSSBS-8288R-CY5)
Lieferant:
Bioss
Hersteller-Artikelnummer::
BS-8288R-CY5
Lokale Artikelnummer::
BOSSBS-8288R-CY5
Beschreibung:
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
VE:
1 * 100 µl
Artikel-Nr:
(BOSSBS-8288R-A350)
Lieferant:
Bioss
Hersteller-Artikelnummer::
BS-8288R-A350
Lokale Artikelnummer::
BOSSBS-8288R-A350
Beschreibung:
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
VE:
1 * 100 µl
Artikel-Nr:
(BOSSBS-8288R-CY3)
Lieferant:
Bioss
Hersteller-Artikelnummer::
BS-8288R-CY3
Lokale Artikelnummer::
BOSSBS-8288R-CY3
Beschreibung:
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
VE:
1 * 100 µl
Artikel-Nr:
(BOSSBS-8288R-CY5.5)
Lieferant:
Bioss
Hersteller-Artikelnummer::
BS-8288R-CY5.5
Lokale Artikelnummer::
BOSSBS-8288R-CY5.5
Beschreibung:
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
VE:
1 * 100 µl
Artikel-Nr:
(BOSSBS-8288R-A488)
Lieferant:
Bioss
Hersteller-Artikelnummer::
BS-8288R-A488
Lokale Artikelnummer::
BOSSBS-8288R-A488
Beschreibung:
Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
VE:
1 * 100 µl
Artikel-Nr:
(04340-500MG)
Lieferant:
Sigma-Aldrich
Hersteller-Artikelnummer::
04340-500MG
Lokale Artikelnummer::
SUPL04340-500MG
Beschreibung:
Water-soluble reagent for the enzymatic photometric determination of hydrogen peroxide.
VE:
1 * 500 mg
Artikel-Nr:
(APOSOR346595-1G)
Lieferant:
APOLLO SCIENTIFIC
Hersteller-Artikelnummer::
OR346595-1G
Lokale Artikelnummer::
APOSOR346595-1G
Beschreibung:
3-Brompyrazolo[1,5-a]pyridin 95+%
VE:
1 * 1 g
Preis auf Anfrage
Lager für diesen Artikel ist begrenzt, kann aber in einem Lagerhaus in Ihrer Nähe zur Verfügung. Bitte stellen Sie sicher, dass Sie in sind angemeldet auf dieser Seite, so dass verfügbare Bestand angezeigt werden können. Wenn das
 noch angezeigt wird und Sie Hilfe benötigen, rufen Sie uns an 1-800-932 - 5000.
Lager für diesen Artikel ist begrenzt, kann aber in einem Lagerhaus in Ihrer Nähe zur Verfügung. Bitte stellen Sie sicher, dass Sie in sind angemeldet auf dieser Seite, so dass verfügbare Bestand angezeigt werden können. Wenn das
noch angezeigt wird und Sie Hilfe benötigen, rufen Sie uns an 1-800-932 - 5000.
Dieses Produkt kann nur an eine Lieferadresse versandt werden die über die entsprechende Lizenzen verfügt. Für weitere Hilfe bitte kontaktieren Sie Ihr VWR Vertriebszentrum.
-Additional Documentation May be needed to purchase this item. A VWR representative will contact you if needed.
Dieses Produkt wurde von Ihrer Organisation gesperrt. Bitte kontaktieren Sie Ihren Einkauf für weitere Informationen.
Dieses Produkt ist Ersatz für den von Ihnen gewünschten Artikel.
Dieses Produkt ist nicht mehr verfügbar. Bitte kontaktieren Sie den VWR Kundenservice.
|
|||||||||
Listenansicht
